myc

c-Myc Peptide Trifluoroacetate is a synthetic peptide corresponding to the C-terminal amino acids (410-419) of human c-myc protein. c-Myc Peptide Trifluoroacetate participates in regulation of growth-related gene transcription.

C-MYC PEPTIDE EPITOPE TFA, the product of the c-myc proto-oncogene, is a helix-loop-helix leucine zipper phosphoprotein that regulates gene transcription in cell proliferation, cell differentiation and apoptosis. This peptide is a human c-myc epitope.

c-Myc Peptide is a useful displacement of c-Myc-tagged fusion proteins bound to anti-c-Myc antibodies in immunoassays. The successful inhibition of antibody binding by c-Myc peptide demonstrates binding is specific. c-Myc peptide participates in the regul

Bleomycin Sulfate (Blenoxane) is a glycopeptide antibiotic, an inhibitor of DNA synthesis. Bleomycin Sulfate causes DNA strand breaks but not RNA strand breaks. Bleomycin Sulfate has antitumor activity.

Valinomycin (NSC-122023) is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.

Vancomycin hydrochloride (Vancomycin HCl) is the hydrochloride salt of vancomycin, a branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci.

Daptomycin (LY146032) is a cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Milbemycin oxime is a broad spectrum antiparasitic, used as a veterinary drug.

Syringomycin E, an antifungal cyclic lipodepsinonapeptide, inhibits the growth of Saccharomyces cerevisiae by interacting with the plasma membrane. It induces K+ efflux, Ca2+ influx, and alterations in membrane potential, associated with channel formation [1] [2].

Globomycin is a lipopeptide antibiotic and an inhibitor of signal peptidase II (LspA). It inhibits the processing of the prolipoprotein by binding irreversibly to the peptidase.

Siamycin I is a tricyclic peptide originally isolated from Streptomyces and has antiviral and antibacterial activities. It is active against laboratory strains and clinical isolates of HIV-1 (ED50s = 0.05-0.45 and 0.89-5.7 μM, respectively), as well as the CBL-20 strain of HIV-2 (ED50 = 0.45 μM), in vitro. Siamycin I inhibits HIV-induced fusion of C8166 T cells with HIV-1-infected CEM-SS cells with an ED50 value of 0.08 μM. It is also active against B. subtilis, M. luteus, and S. aureus (MICs = 1.6-6.3 μg/ml). Siamycin I inhibits autophosphorylation of the E. faecalis quorum sensing kinase FsrC induced by gelatinase biosynthesis-activating pheromone (GBAP).

Arylomycin A2, a lipopeptide antibiotic, functions as a type I signal peptidase (SPase I) inhibitor. It exhibits antibacterial properties [1].

Virginiamycin M1 (Pristinamycin IIA) is a macrocyclic lactone peptide antibiotic and is a member of the streptogramin A group of antibiotics.

N-Nonyldeoxynojirimycin (NN-DNJ) is an inhibitor of acid α-glucosidase and α-1,6-glucosidase (IC50s = 0.42 and 8.4 μM, respectively).

Capreomycin sulfate (Capastat sulfate) , a cyclic peptide antibiotic, binds to the 70S ribosomal unit leading to inhibition of protein synthesis.

Capreomycin is a polypeptide antibiotic originally isolated from S. capreolus. It is active against M. tuberculosis (MIC = 10 µg/ml). Capreomycin binds to both the 30S and 50S ribosomal subunits, inhibiting protein synthesis.

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.

Balhimycin, a glycopeptide antibiotic produced through the fermentation broth of Amycolatopsis sp., exhibits anti-bacterial effects against staphylococci and anaerobes [1].

Enviomycin (Tuberactinomycin N) is an antibacterial antibiotic utilized in researching chronic cavitary pulmonary tuberculosis [1].

Aurantimycin A (Adipogen), a depsipeptide antibiotic, exhibits potent efficacy against Gram-positive bacteria and serves as a substrate for the LieAB transporter [1] [2].

Actinomycin X2 (Actinomycin V) is a compound synthesized by various species of Streptomyces. It displays potent inhibition against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.25 μg/mL. Actinomycin X2 possesses potential applications in the treatment of both cancer and bacterial infections.

Tat-QFNP12 is a peptide that combines a transcriptional transactivator (Tat) transmembrane domain with an inhibitor targeting the interaction between N-Myc downstream regulated gene 2 (NDRG2) and protein phosphatase Mg2+/Mn2+ dependent 1A (PPM1A). This compound effectively mitigates blood-brain barrier endothelial tight junction disruption caused by elevated levels of matrix metalloproteinase-9 (MMP-9), alleviates cerebral edema, and promotes spontaneous activity along with symmetric limb movement in a mouse model of subarachnoid hemorrhage induced by endovascular puncture. These benefits are observed at a dosage of 20 mg/kg.